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Magnitude of end.stage renal disease in IDDM: A 35 year follow-up
study. Significant improvements were made during the last two decades in
the treatment of IDDM patients. To assess the risk of ESRD in a
population that was exposed to these improvements, we determined the
cumulative incidence of ESRD in a cohort of 142 whitc patients who were
aged less than 21 years when they came to the Joslin Diabetes Center in
1959 with recently diagnosed IDDM. The first case of ESRD occurred
after 13 years of IDDM, and a total of 25 cases have developed by 35 years'
duration (cumulative incidence 21.3%). Median survival after the diagno-
sis of ESRD for the 16 patients who began dialysis was only 3.5 years. A
strong predictor of the development of ESRD was the level of glycemic
control during the first two decades of IDDM. ESRD developed in 36.3%
of patients in the worst tertile for glycemic control hut only in 14.4% and
9.2% of those in the middle and best tertiles. In comparison with two
population based studies, the onset of ESRD in the Joslin Cohort was
postponed by about five years. This advantage is more plausibly attribut-
able to differences arising after the diagnosis of diabetes than to referral
of less severe cases of IDDM to the Joslin Diabetes Center. What
differences in diabetes care accounted for the postponement of ESRD
cannot be discerned from comparisons among published studies, but likely
candidates include Joslin's long-term advocacy of good glyeemie control
and the prompt implementation of new clinical interventions, such as
antihypertensive treatment.
Diabetic nephropathy, one of the most serious late complica-
tions of juvenile-onset insulin-dependent diabetes mellitus
(TDDM), develops in one out of three patients [1, 21. In a majority
of those affected, it progresses to end-stage renal disease (ESRD)
and requires renal replacement therapy [1, 21. Coronary athero-
sclerosis is accelerated in nephropathy, so most succumb to
coronary artery disease despite renal replacement therapy, and
these deaths account for much of the premature mortality in
IDDM [3].
Few data have been acquired from recent cohort studies of the
occurrence of ESRD in IDDM. Such studies are necessary to
assess the effectiveness of improvements that have been made
during the last three decades in the care for patients with IDDM.
These include tools to improve glycemic control such as the
introduction of measurements of hemoglobin A1 [4], antihyper-
tensive treatment to retard progression of proteinuria to ESRD
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[5, 6], and hemodialysis and renal transplant to maintain those
who developed ESRD [7]. Contemporary estimates of the risk of
ESRD in IDDM are also critical for the development of new
preventive programs [8, 9]. The cost and effectiveness of any new
program must be measured against the cost and effectiveness of
existing programs. For example, recent clinical trials have dem-
onstrated, in very select populations, that both intensive glycemic
control and treatment with ACE inhibitors reduce the risk of
diabetic nephropathy [10—13]. It remains to be determined,
however, how much these new therapeutic protocols will reduce
the overall risk of ESRD when implemented in the care of all
patients.
This report describes the occurrence of ESRD in the cohort of
patients who came to the Joslin Diabetes Center in 1959 with a
recent diagnosis of TDDM. They have been followed until January
1, 1994. During this interval, the majority of the cohort remained
in the care of the Joslin Diabetes Center, an institution in which
control of hyperglycemia has been emphasized in patient care. In
the 1970's and 1980's this cohort was also exposed to antihyper-
tensive treatment and had access to treatment with replacement
renal therapy [5—7, 14].
Methods
All patients (N = 142) with newly diagnosed IDDM, aged < 21
years, who came to the Joslin Clinic during an 18 month interval
centered around 1959 were included in the present study. Addi-
tional eligibility criteria were that all were Caucasian residents of
Massachusetts at the time of their first visit to the clinic in that
interval. Previously, this cohort had been followed up to 1981 as a
part of an earlier investigation [2, 3].
For each individual, the medical records at the Joslin Clinic
were examined for any evidence of renal function impairment.
Individuals who had their last Joslin Clinic visit before January 1,
1994, were interviewed by phone regarding doctor-diagnosed
kidney disease, hemodialysis, or kidney transplantation. In cases
of death, information was sought from private physicians, autopsy
reports, and death certificates regarding the circumstances of the
death and all conditions present at that time. Information from all
these sources was used to determine whether a patient had
developed ESRD and, if so, the date of its onset.
Patients were diagnosed as having ESRD if they underwent
long-term dialysis, or if they died due to other causes but had
renal failure (serum creatinine  5.0 mg/dl or 440 j.tmol/liter)
documented at least one month prior to death. ESRD onset was
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Characteristic
Men
N = 77
Women
N = 65
Total
N = 142
Age at diagnosis of IDDM years 11.2 5.9 11.7 4.8 11.4 5.4
Visited Joslin Clinic after 1991 % 28.5 35.4 31.7
Did not visit Joslin after 1991 41.6 32.3 37.3
but alive as of 1 Jan 1994 %
Dead as of 1 Jan 1994 % 27.3 24.6 26.1
Status unknown as of 1 Jan 1994 % 2.6 7.7 4.9
ESRD diagnosed before 1 Jan 1994 % 18.2 16.9 17.6
the date that dialysis began or the date of death for those not
undergoing dialysis. Patients who developed ESRD were matched
against the file of registrants in the Medicare's End-Stage Renal
Disease Program to find out what proportion of patients from our
cohort were registered. The matching data were full name, date of
birth, place of birth, and Social Security Number if available.
Instances of imperfect hut nearly complete matches were investi-
gated until the discrepancies were resolved or the mismatch was
confirmed by additional data.
An index of the frequency of hyperglycemia, the same as used
in the previous study of persistent proteinuria and glycemic
control, was used in the present study to determine the relation-
ship between levels of glycemic control during the first 20
post-pubertal years of diabetes and the development of ESRD [2].
Briefly, the index is the proportion of clinic visits in which severe
hyperglycemia was present. Hyperglycemia was considered severe
on the date of a clinic visit if a patient had a fasting blood glucose
value  180 mg/dl, or during postprandial intervals < 1.4 hours,
1.5 to 2.4 hours, 2.5 to 3.4 hours, or  3.5 hours a blood glucose
value  240, or 220, or 200 or 180 mg/dl, respectively. The index
was calculated by five-year intervals of age from age 10 to 30 years.
Specifically, the index of hyperglycemia was the number of clinic
visits with severe hyperglycemia during a five-year age interval
divided by the total number of clinic visit during that interval. If
the number of clinic visits during an interval was less than four,
the corresponding index of hyperglycemia was considered missing.
If no index of hyperglycemia was available for any interval
between ages 10 and 30 years, the patient was considered a
non-attender (26 of 142 patients, 18.3%). Otherwise, the patient
was classified according to the average of the intervals for which
the index was calculated.
Incidence and cumulative incidence rates were used to measure
the frequency of the occurrence of end-stage renal disease. The
cumulative incidence rates were calculated over specific time
intervals using life table methods [15, 16]. In this study two end
points (death and ESRD) were considered, and patients contrib-
uted person years of follow up until the year of the occurrence of
these end points. Patients who were traced to the present and did
not have either end point contributed person years until January
1, 1994. Patients who were untraced contributed person years
until the year of the last clinic visit or hospitalization when serum
creatinine was measured. Differences among incidence rates were
tested by a chi-square test [16]. Differences among cumulative
incidence rates were tested by log-rank tests [15, 16].
Duration of IDDM, years
Fig. 1. Cumulative incidence of end-stage renal disease (ESRD) accordLng
to duration of IDDM and according to age at Onset of IDDM. Closed
rectangles represent those diagnosed between ages 11 and 20 years; open
circles represent those diagnosed before age 11 years. Asterisks indicate
point at which the two curves are significantly different (P = 0.04).
Results
Risk of ESRD
Characteristics of the study group according to sex are shown in
Table 1. The average age at onset of IDDM was 11 (range 0 to 20)
years for males and 12 (range 0 to 20) years for females. As of 1
January 1994, 31.7% of the entire cohort of patients were still
visiting the Joslin Clinic (at least 1 visit after January 1, 1991),
26.1% were dead, 4.9% were untraced, and the remaining 37.3%
were alive but in the care of other medical facilities. No significant
difference between males and females was observed for the
characteristics shown in Table 1.
The first case of ESRD occurred in 1973 and began dialysis in
December of that year. Since then, ESRD has developed in a total
of 25 patients, 17.6% of the cohort. Of these, 16 (64%) began
dialysis and were registered in the Medicare End Stage Renal
Disease Program. Another three began dialysis but died promptly
and were not registered. The remaining six individuals had renal
failure as defined by serum creatinine level but were not put on
dialysis before they died. One refused dialysis and the others were
either too ill due to other medical problems or died suddenly
before dialysis began.
Figure 1 shows the cumulative incidence of ESRD according to
duration of diabetes in two subgroups defined by age at onset of
IDDM. The first cases of ESRD occurred after 13 years of
diabetes in the 82 patients with diabetes diagnosed between age
11 and 20 years. After 35 years of diabetes, ESRD had developed
in 13 of them, giving a cumulative incidence of 18.3% 4.6%. In
the 60 patients with diabetes diagnosed before age 11, the first
case of ESRD did not occur until after 19 years of diabetes, about
six years later than the previous group. After 35 years of diabetes,
ESRD had developed in 12 patients in this subgroup, giving a
cumulative incidence of 22.7% 5.8%. Therefore, the risk in the
long run was similar regardless of age of onset of IDDM, but in
the window 18 and 19 years of IDDM, the risk was significantly
higher in those with IDDM diagnosed after age 11 than those
diagnosed at younger ages (P = 0.04). When exposure to diabetes
Table 1. Characteristics of the 1959 cohort according to gender 40 -
30
20ci)0
ci)0
a 19 of the 25 patients with ESRD began dialysis, 16 of whom entered 10
Medicare's ESRD Program; the remaining 6 died in years 1976, 1979,
1987, 1990, 1990, and 1991 (see text for details).
0
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Post-pubertal duration Incidence
of IDDM years Person-years rate/1000
0—9 1371 —
10—14 672 1.5 (1)
15—19 636 12.6 (8)
20—24 574 10.4 (6)
25—29 450 17.8 (8)
30—34 310 6.4 (2)
Total 4012 6.2 (25)
before age 11 years was disregarded so that the cumulative
incidence of ESRD was computed according to post-pubertal
duration of diabetes, the two curves were virtually identical (data
not shown). In the total group, the cumulative incidence rate of
ESRD after 35 years of post-pubertal duration of IDDM was
21.3% 3.9%.
The incidence rate of ESRD during specific intervals of post-
pubertal duration of diabetes is presented in Table 2. The first
ease occurred between the 10th and 14th year of post-pubertal
diabetes (incidence rate 1.5/1000 person-years). The incidence
rate then increased with duration of diabetes, reaching a peak of
17.8/1000 person-years between the 25th and 29th year, and
declined afterwards to 6.4/1000 person-years. While the decline is
not statistically significant with the small number of person-years
of follow-up after 30 years post-pubertal duration, it is consistent
with the decline in the incidence rate of proteinuria in long
duration diabetes.
Association of glycemic control and the risk of ESRD
Au index of severe hyperglycemia, the same as that in the
previous study of this cohort [2], was used to examine the
relationship of the risk of ESRD to glycemic control. Stated
simply, severe hyperglycemia was defined as a blood sugar above
the 66th percentile of all clinic blood sugars, specific to a time
since last meal (see above). The index of hyperglycemia was the
proportion of a patient's clinic visits in which the blood sugar was
in the severe hyperglycemia range. The group was divided into
tertiles according to the index of hyperglycemia (lowest = 0% to
11.9%, middle = 12.0% to 25.0%, and highest  25.1%) to
calculate the cumulative incidence rate of ESRD over 35 years of
IDDM according to glycemic control (Fig. 2). Those with the
poorest control (severe hyperglycemia on more than I of 4 clinic
visits) had a significantly higher risk of ESRD 36.3% 8.7% (P =
0.02) than the middle and best tertiles (14.4% 6.0% and 9.2%
5.1%, respectively). No index of hyperglycemia can be calcu-
lated for non-attenders (the 26 patients who never attended clinic
more than three times in any five-year interval between age 10 and
30 years). For them, the cumulative incidence of ESRD after 35
years of post-pubertal IDDM was 3 1.3% 12.0%, similar to the
clinic attenders who had the poorest glycemic control hut not
significantly different from the group of attenders as a whole
(19.9% 4%; P 0.39).
Association between ESRD and mortality
Out of 25 individuals who developed ESRD (at an average age
of 35 5.6 years), 18 had died as of January 1, 1994, at an average
Post-pubertal duration of IDDM, years
Fig. 2. Cumulative incidence of ESRD according to duration of IDDM and
according to tertile of the index of hyperglycemia. Closed rectangles repre-
sent the tertile with the highest index of severe hyperglycemia (N = 37);
open triangles represent the middle tertile (N = 39), and open circles
represent the third (N - 40) with the lowest index of hyperglycemia. The
differences among the curves are statistically significant, P = 0.017. The
remainder of the group (N = 26) were non-attenders, so no index of
hyperglycemia could be calculated. Their curve was very similar to that for
the tertile with the highest index of hyperglycemia.
age of 38 6.5 years. Survival in this group was very poor, 50%
of these patients survived 2.5 years after diagnosis of ESRD and
25% survived 8.5 years. Survival was slightly better if consider-
ation was restricted to patients who began dialysis, some of whom
subsequently had a renal transplant. Half of these patients
survived 3.5 years and 25% survived nine years.
In addition to the 18 deaths that were preceded by ESRD, 19
deaths occurred in the absence of ESRD. Three occurred before
the age of 20 (2 DKA and 1 suspected suicide). Among the
remaining 16 (average age 38 7.4 years), there were 12 due to
coronary artery disease (including sudden death), 2 to cerebro-
vascular disease, and 2 due to other causes. As was found for
ESRD, exposure to diabetes before age 11 did not contribute to
mortality. Cumulative mortality due to all causes in this cohort
was 29.0% 4.2% after 35 years of post-pubertal duration of
IDDM. If renal replacement therapy were not available and
patients had died at the time of the diagnosis of ESRD, cumula-
tive mortality would have been worse, 33.4% 4.2%.
Comparisons with other studies
Reports from two studies have published incidence rates of
ESRD in IDDM patients that can be compared to this study. Both
studied geographically-defined populations. In one study, the
investigators showed that the cumulative incidence of ESRD up to
20 years duration of IDDM was significantly later among whites in
Allegheny County, Pennsylvania, than in patients in Japan [17]. In
comparison with these two populations, the cumulative risk in the
present study was even later (Fig. 3). Interestingly, the cumulative
risk in the half of the Joslin Cohort with the worst hyperglycemia
(the highest tertile of the index of hyperglycemia combined with
non-attenders), was superimposable on the Allegheny County
curve (reaching 12% at 25 years rather than 23 years, data not
shown), whereas the cumulative risk in the half of the cohort with
Table 2. Incidence of ESRD according to post-pubertal duration of
IDDM 40
Number of cases of ESRD
C
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Duration of IDDM
Fig. 3. Cumulative risk of dialysis according to follow-up time in patients
with IDDM in Japan (filled rectangles), Allegheny County, PA, (open
triangles), and the present Joslin cohort study (open circles). The average
durations of diabetes at the beginning of follow-up in the Japanese and
Allegheny County studies were 3.5 and 4.4 years, respectively. Therefore,
four years were added to the published follow-up times to make them
approximate duration of IDDM. Similarly, for this figure, the Joslin
Cohort was plotted according to duration of diabetes rather than post-
pubertal duration.
less frequent hyperglycemia (the lower 2 tertiles of the index of
hyperglycemia) had only reached 11.4% by the end of follow-up.
In the second study, investigators estimated the age-specific
incidence rate of ESRD in two populations, black and white
patients with IDDM in Southeastern Michigan, and showed that
the incidence rate peaked earlier (and higher) in blacks than in
whites (ages 25 to 29 compared to 30 to 34 years) [18]. It peaked
five years later yet (ages 35 to 39 years) in the Joslin Cohort (Fig.
4). In all three populations, the incidence rate fell off steeply after
the peak, a pattern consistent with the exhaustion of a pooi of
susceptible individuals within each population. An indication of
the size of the susceptible pool is given by the cumulative
incidence rate of ESRD up to age 50 years, calculated from these
age-specific rates: 34.9% in Michigan blacks, 28.6% in Michigan
whites, and 21.5% in the white Joslin Cohort. In the half of the
Joslin Cohort with the worst hyperglycemia (the highest tertile of
the index of hyperglycemia combined with non-attenders), the
cumulative incidence up to age 50 years was 36.2% 7.5%, while
it was only 11.4% 3.8% (P = 0.003) in those with less frequent
hyperglycemia (the lower two tertiles of the index of hyperglyce-
mia). The cumulative risk of 36.2% was quite close to that in the
two Michigan populations.
Discussion
Significant improvements have been made during the last two
decades in the treatment of IDDM patients at risk of ESRD, as
well as in the treatment of patients with ESRD. In the present
study, we examined the cumulative incidence of ESRD in a cohort
of white patients who came to the Joslin Diabetes Center in 1959
with recently diagnosed, juvenile-onset IDDM and who were
followed until January 1, 1994. During the first 20 years of
diabetes, a majority of these patients were under the care of the
Joslin Diabetes Center, an institution where control of hypergly-
Age
Fig. 4. Age specific incidence rates of diabetic ESRD in Southeastern
Michigan among black patients with IDDM (filled rectangles) and among
white patients with JDDM (open triangles), and in the Joslin cohort of white
patients with IDDM (open circles). The six Out of 25 Joslin patients who did
not begin dialysis, died at ages 30, 31, 31, 38, 44, and 46 years. If they are
withdrawn from the analysis, the incidence rate for the Joslin cohort is
even lower than the Michigan rates.
cemia has been a main goal of patient education and care. During
the 1970s and 1980s these patients were exposed to antihyperten-
sive treatment and had access to renal replacement therapies
through Medicare's ESRD Program once they developed ESRD.
Despite improvements in the treatment of hypertension, almost
one fourth of these juvenile-onset IDDM patients developed
ESRD during 35 years of diabetes. Although the majority
of affected patients were enrolled in the Medicare ESRD Pro-
gram, median survival after the beginning of dialysis was only
3.5 years.
The pattern of occurrence of ESRD according to duration of
IDDM in our cohort parallels the previously described pattern of
occurrence of persistent proteinuria, just shifted about 10 years
later [1, 21. The first case of ESRD occurred after 13 years of
diabetes, and then the incidence rate increased to a peak in the
interval 25 to 29 years of diabetes and subsequently declined.
A strong predictor of the development of ESRD in our cohort
during the third and fourth decade of IDDM was the level of
glycemic control during the first two decades of IDDM. The risk
of ESRD in the tertile with the poorest glycemic control (highest
tertile) was almost threefold higher than in the middle tertile, and
fourfold higher than the tertile with the best glycemic control
(lowest tertile). Patients in the highest tertile presented for clinic
appointments with severe hyperglycemia at least once out of every
four visits, while the rest of the patients were more consistent in
keeping below that range. This fourfold gradient for the risk of
ESRD is slightly steeper than the gradient we reported previously
for persistent proteinuria [21. Recognizing the crudeness of this
index of severe hyperglycemia as an indicator of glycemic control,
one can expect an even steeper gradient if the analysis could have
been based on the level of hemoglobin A1. An implication of a
very steep gradient is that a threshold may exist in the dose
response relationship.
Although we found a strong relationship between the frequency
of severe hyperglycemia and the risk of ESRD, it is not clear how
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much this "pattern" of poor glycemic control can be changed and
how much it is controlled by the same genetic factors that
determine susceptibility to diabetic nephropathy. Two facts argue
against a common genetic determinant of poor glycemic control
and susceptibility to diabetic nephropathy. The first is that the
cumulative risk of ESRD in the half of the study group with
poorest glycemic control was 36.2%, nearly the same as the
prevalence of susceptibility to nephropathy in all patients with
IDDM [21. If both poor glycemic control and susceptibility to
nephropathy were due to the same genetic determinants, one
would expect a much higher risk of nephropathy in the subgroup
with poorest glycemic control. The second argument against this
hypothesis is based on the recent DCCT results. In highly
motivated patients, intensive diabetes treatment results in im-
proved glycemic control to such a degree that 90% of the study
group is able to maintain a hemoglobin Ale below 8.1%, a
threshold for risk of microalbuminuria [19]. If this can be accom-
plished in ordinary IDDM patients, the majority of cases of ESRD
in TDDM patients would be prevented or delayed. Such an effect
on the risk of persistent proteinuria seems to have been accom-
plished in one Swedish community [201.
In agreement with previous reports, in which the risk of
persistent proteinuria was high among non-attenders [2, 21], we
found that patients in this study who attended clinic infrequently
had a very high risk of ESRD. According to a recent study, levels
of glycosylated hemoglobin are significantly higher in such pa-
tients at the time of their clinic visits, as well as when they are not
attending the clinic [22]. Moreover, these patients are from lower
socioeconomic strata or dysfunctional families. Aiiother study
suggests that patients who attend clinic infrequently have health
beliefs that downplay the value of physician-patient interchanges
[23]. All of these findings point to the critical need for the
development of new strategies to engage IDDM patients in
preventive programs (such as intensive diabetes treatment)
against ESRD.
New strategies for engaging TDDM patients with nephropathy
in therapeutic programs to retard progression to ESRD are
equally important. Since the early 1980s, antihypertensive treat-
ment of patients with persistent proteinuria has been advocated
[5, 6]. Such treatment was implemented at the Joslin Diabetes
Center in the early 1970s, so the patients in the 1959 Cohort who
remained under the care of the clinic were exposed to this
treatment [14]. Most likely, the non-attenders were not treated for
hypertension, and this may account for some of the excess ESRD
among that group. The superiority of ACE inhibitors over con-
ventional antihypertensive drugs in reducing the risk of ESRD in
patients with diabetic nephropathy has recently been demon-
strated in clinical trials. This improvement can be translated into
patient care only if the disengaged patients are targeted for early
screening and therapeutic programs.
A majority of the patients in our study who developed ESRD
entered the Medicare ESRD Program. The main reason for
ESRD patients in this cohort not being entered into the Medicare
ESRD program was their death within months of the diagnosis of
ESRD. While some of them had other medical problems more
pressing than their renal failure, the prompt demise of many of
them was not anticipated. Mainly, this reflects the high risk of
coronary disease in this population, particularly after the age of 35
years [24]. An important implication is that the registrations of
diabetic patients in Medicare's ESRD Program underestimates
the number of incident cases of ESRD. This problem of under-
estimation also extends to the population-based studies in Alle-
gheny County [171 and Southeastern Michigan [18]. In both
studies, the end point was the date when renal replacement
therapy began. In the Joslin cohort, six patients with ESRD did
not begin dialysis. If they are withdrawn from the analysis, the
cumulative risk after 35 years of IDDM decreases to 16.0%, and
the disparity with the other studies is even larger.
Finally, these differences between the incidence rate of ESRD
in the Joslin Cohort and other populations have important
implications regarding the potential for reducing the devastating
impact of diabetic renal disease. While the lifetime risk of ESRD
in white patients with IDDM at Joslin Diabetes Center was similar
to that in other locales, the distribution of onsets of ESRD was
delayed about five years relative to Allegheny County and South-
eastern Michigan. In contrast, within Michigan, the distribution of
age at onset of ESRD among blacks was shifted even earlier by
five years than that among whites. The fact that the lifetime risk of
ESRD in the Joslin Cohort was similar as that in whites elsewhere
[1, 18], indicates that patients who came to the Joslin Diabetes
Center at the diagnosis of IDDM were not less susceptible to
ESRD, therefore the delayed onset of ESRD must he related to
the setting of the treatment. Patients in the Joslin Cohort became
engaged with the medical care system from the onset of their
diabetes. Although a certain proportion of them became disen-
gaged later, most were exposed to the education programs of this
center that advocated strict control of glycemia. By contrast, the
data from Allegheny County and Southeastern Michigan included
many patients who, from the onset of their diabetes, were remote
from close medical follow-up and held diverse attitudes toward
medical expertise. The position of black patients with IDDM in
Figure 4 is consistent with their being even more remote from
close medical follow-up, perhaps for cultural as well as economic
reasons. If this interpretation of the differences among distribu-
tions of onset of ESRD is valid, these differences indicate that
relatively simple measures (in comparison with the intensive
diabetes treatment achieved by the DCCT) are required to
postpone significantly the devastating impact of ESRD on the
population of patients with IDDM.
The strengths and shortcomings of our study should be men-
tioned. Data on the experience of patients of the Joslin Diabetes
Center were based on a fixed cohort of newly diagnosed IDDM
patients, some of whom were referred to the center most likely
because their diabetes was especially difficult to control from the
outset. This cohort was followed for 35 years with nearly complete
follow-up and documentation of renal status as of 1 January, 1994.
Hence, the delayed risk of ESRD in the Joslin Cohort relative to
the other studies likely reflects an effect of their exposure to the
Center's educational and therapeutic protocols, as well as the
early introduction of new measures to control hyperglycemia and
hypertension. It must be recognized, however, that the center did
not have an active policy to retain patients under its care during
the relevant decades, and its education program did not achieve
"fair" glycemic control in at least one third of the population. If
the Center had intensified the treatment of diabetes in the subset
of this cohort with the worst hyperglycemia and improved their
glycemic control, it is likely that the onset of ESRD would have
been postponed 10 years in that subgroup.
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